Skip to content

Influence of different restrictive infusion strategies on blood loss during controlled low central venous pressure hepatectomy

Influence of different restrictive infusion strategies on blood loss during controlled low central venous pressure hepatectomy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098242
Enrollment
Unknown
Registered
2025-03-05
Start date
2025-03-07
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatopathy

Interventions

Group A:Before the stage of hepatic parenchyma dissection,Normal saline was injected at the rate of 1mL/(kg/h).
Group B:Before the stage of hepatic parenchyma dissection,Normal saline was injected at the rate of 3mL/(kg/h).
Group C:Before the stage of hepatic parenchyma dissection,Normal saline was injected at the rate of 5mL/(kg/h).

Sponsors

The Second Affiliated Hospital of Kunming Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing elective hepatectomy; 2. Age 18-70 years old; 3. ASA grade ?~?; 4. New York Heart Function Grade I to II; 5. Liver function Child-Pugh A/B grade; 6. There are no other major surgical procedures (spleen, bowel, pancreas surgery).

Exclusion criteria

Exclusion criteria: 1. Obese patients (BMI > 32kg/m²); 2. Patients with severe cardiovascular and cerebrovascular diseases (history of hypertrophic cardiomyopathy, New York heart Function Class III or above, ejection fraction <50%, myocardial infarction, cerebral infarction, and cerebral hemorrhage); 3. Patients with renal insufficiency or renal failure, dyspnea or respiratory failure; 4. Patients with coagulation disorders ( according to the 2024 diagnostic criteria for coagulation disorders) or preoperative anticoagulation therapy; 5. Anemia: patients with total hemoglobin concentration less than 110g/L; 6. Patients with contraindications of arterial and central venipuncture; 7. Refuse to sign informed consent.

Design outcomes

Primary

MeasureTime frame
Operative blood loss;

Secondary

MeasureTime frame
Blood transfusion rate;Grading of surgical field;Arterial blood lactate level; Heart rate;Mean arterial pressure;Stroke Volume;Cardiac Output;Cardiac Output index;Stroke Volume Variation;Systemic Vascular Resistance;Central Venous Pressure;Urine volume;Fluid volume;Dosage of norepinephrine;Nitroglycerin dosage;Number of liquid shocks;The number of hepatic portal blocks;Operation duration;Hepatectomy duration;Albumin;Alanine Aminotransferase;Aspartate Aminotransferase;Creatinine;Total Bilirubin;Direct Bilirubin;Blood Urea Nitrogen;Creatine Kinase Isoenzymes;Myoglobin;High-sensitivity Troponin;N-telencephalic natriuretic peptide precursor;Prothrombin Time;Activated Partial Thromboplastin Time ;Fibrinogen;D-Dimer;Fibrinogen Degradation Products;Extubation Time;ICU Stay;Length of stay;Adverse reaction;Complication;Total hospital expenses;30-day postoperative mortality;Residual alkali in whole blood;pH value;Total hemoglobin concentration;

Countries

China

Contacts

Public ContactOuyang Jie

The Second Affiliated Hospital of Kunming Medical University

oulikon77@sina.com+86 158 1212 8771

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026